cold chain raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
An expert in US constitutional law from King's College London stated to the BBC that it is not clear if the strike would fall under the presidential powers granted by the anti-terrorist Authorization for Use of Military Force of 2001 (AUMF), but that the administration's use of the term "narco-terrorists" may hint at this being their legal justification. According to the Center for Strategic and International Studies (CSIS), for several decades AUMF "has substituted for a formal declaration of war", and was used in 2001 to authorize war against "nations, organizations, or persons [the president] determines planned, authorized, committed, or aided" the attacks of 11 September or "harbored such organizations or persons". CSIS states that this authorization has been "used as a controversial legal basis for US counterterrorism operations against the Taliban, al-Qaeda, and other organizations" and Joe Biden "did not seek congressional authorization for its frequent strikes against the Houthis in Yemen". Law professor Gabor Rona argued in a 2 October 2025 Lawfare article that, while he agreed with other analysts that the strikes were unlawful, they reflected a predictable overreach that followed the precedents established during the George W. Bush, Barack Obama and Joe Biden administrations following the 11 September attacks. Political scientist Peter Feaver noted that every presidential administration since Ronald Reagan's considered deploying military force in the war on drugs, but only the second Trump administration followed through.
The likelihood of ionization is a function of the filament temperature, the work function of the filament substrate and the ionization energy of the element. This is summarised in the Saha–Langmuir equation:
This makes it a highly effective treatment for negative and cognitive symptoms of schizophrenia since 5HT2A antagonism increases dopamine release in the mesocortical pathway which is hypoactive in those with schizophrenia. Interestingly, lumateperone indirectly augments glutamatergic neurotransmission through its activity at D1 receptors, which causes phosphorylation of GluN2B subunits of NMDA receptors in the mesolimbic pathway. This is significant since NMDA receptor hypofunction, reduced D1 binding, and glutamatergic abnormalities have been implicated in contributing to the cognitive and negative symptoms of schizophrenia. It has also been identified as a potent vesicular monoamine transporter 2 (VMAT2) inhibitor (IC50Tooltip half-maximal inhibitory concentration = 62 nM).
This energy is carried away as kinetic energy by the electron and antineutrino. Because the reaction will proceed only when the Q value is positive, β− decay can occur when the mass of atom AZX is greater than the mass of atom AZ+1X′.
Sources: en.wikipedia.org
== Toxicity == This species was for a long time highly regarded as one of the tastier edible species (and by some authors still is) and was sold in European markets. Medieval French knights allegedly reserved this species for themselves, leaving the lowly bovine bolete (Suillus bovinus) for the peasants. Concern was first raised in southwestern France. People who have been poisoned have all had three or more meals containing T. equestre within the last two weeks prior to treatment. One to four days after their last meal containing the fungus, patients reported muscle weakness, sometimes accompanied by pain. This weakness progressed for another three to four days, accompanied by a feeling of stiffness and darkening of the urine. Periods of nausea, sweating and reddening of the face were also reported, with no fever present. There have been no reported cases of poisoning in North America, and there is speculation that the respective mushrooms may in fact be different species that are very similar in appearance. Molecular research shows that multiple species may have been identified as the synonym T. flavovirens on the West Coast. There are reports of deaths of patients being treated for T. equestre poisoning. The poison in this mushroom remains unknown. The mechanism of poisoning is suspected to be rhabdomyolysis, damaging of the cell membrane of skeletal muscle fibres. In this disorder, the oxygen-carrying muscular protein myoglobin is released and appears in urine, resulting in symptoms such as muscle pain and brownish coloration of the urine.
"It would be strange indeed if the United Kingdom government, exercising no internal power in Rhodesia, were given the right to exercise the prerogative of clemency." The Judge President Sir Vincent Quénet and Justice Hector Macdonald agreed, and the application was dismissed. Justice John Fieldsend of the High Court's General Division resigned in protest, writing to Gibbs that he no longer believed the High Court to be defending the rights of Rhodesian citizens. Dhlamini, Mlambo and Shadreck were hanged on 6 March. On 23 July 1968, the Privy Council in London ruled in Madzimbamuto's favour, deciding that orders for detention made by the Rhodesian government were invalid regardless of whether the 1961 or 1965 constitution was considered effective. It declared the latter, "revolutionary" constitution illegal, and ruled that the former was overridden by the Southern Rhodesia Act 1965, which had effectively outlawed the Rhodesian legislative, administrative and legal authorities in British law. Lord Reid, delivering the majority opinion (Lord Pearce dissented), argued that the "usurper" government, though the effective master of Rhodesia, could not be considered lawful as the UK government was still attempting to regain control and it was impossible to say whether or not it would succeed.
A study in Europe suggested the gene marker is only relevant for East Asians. This has clinical relevance as it is agreed upon that prior to starting a medication such as allopurinol in a patient of Chinese descent, HLA-B*58:01 testing should be considered. Based on the Asian findings, similar studies in Europe showed 61% of allopurinol-induced SJS/TEN patients carried the HLA-B58 (phenotype frequency of the B*5801 allele in Europeans is typically 3%). One study concluded: "Even when HLA-B alleles behave as strong risk factors, as for allopurinol, they are neither sufficient nor necessary to explain the disease." Other HLA associations with the development of SJS, SJS/TEN, or TEN and the intake of specific drugs as determined in certain populations are given in HLA associations with SCARs.
=== Modulation === A neurotransmitter may have an excitatory, inhibitory or modulatory effect on the target cell. The effect is determined by the receptors the neurotransmitter interacts with at the post-synaptic membrane. Neurotransmitters influence trans-membrane ion flow either to increase (excitatory) or to decrease (inhibitory) the probability that the cell with which it comes in contact will produce an action potential. Synapses containing receptors with excitatory effects are called Type I synapses, while Type II synapses contain receptors with inhibitory effects. Thus, despite the wide variety of synapses, they all convey only these two types of messages. The two types have different appearances and primarily act on different parts of neurons. Receptors with modulatory effects are spread throughout all synaptic membranes and binding of neurotransmitters sets in motion signaling cascades that help the cell regulate its function. Binding of neurotransmitters to receptors with modulatory effects can have many results. For example, it may increase or decrease in sensitivity to future stimuli by recruiting more or fewer receptors to the synaptic membrane. Type I (excitatory) synapses are typically located on the shafts or the spines of dendrites, whereas type II (inhibitory) synapses are typically located on the cell body. In addition, Type I synapses have round synaptic vesicles, whereas the vesicles of type II synapses are flattened.
== Publications == The exile organization maintained a publication apparatus through the Bulletin of the Information Bureau of the People's Union for the Defense of the Motherland and Freedom, which circulated reports, political materials, and organizational information among émigré and underground anti-Bolshevik circles.
Sources: en.wikipedia.org
December 28, 1967: Authorization of contraception by the Neuwirth Law; however, its implementation decrees would not be published until 1971. January 24, 1968: Decree on common provisions applicable to civil servants in the active services of the national police: unless an exception is made, a woman cannot be appointed to a position within the active services. May 24, 1969: Decree setting the amount of the single salary allowance and the stay-at-home mother's allowance. June 4, 1970: In the Civil Code, "joint parental authority" replaces "paternal authority," and "both spouses jointly ensure the moral and material guidance of the family." July 15, 1970: Law concerning the École Polytechnique, which notably allows women to take the entrance exam and sets the conditions for their employment after graduation. August 26, 1970: Founding of the Women's Liberation Movement (MLF), marked by the laying of a wreath "to the wife of the unknown soldier" on the Tomb of the Unknown Soldier beneath the Arc de Triomphe in Paris. December 23, 1970: Decree increasing the rate of daily rest allowances for maternity insurance under the general social security system. April 5, 1971: Publication of the "Manifesto of the 343" in Le Nouvel Observateur: signed by 343 women — including celebrities — declaring they had undergone an abortion and demanding the right to free abortion. April 16, 1971: Ministerial order regarding the Women's Work Committee, replacing the Study and Liaison Committee on Women's Work Issues. June 10, 1971: Law on parentage.
== Clinical significance == Clinical attachment loss is one of the three characteristic factors of periodontitis. In clinical practice, CAL is the primary feature assessed to diagnose periodontitis. Periodontitis is diagnosed when
== History == In 1935, David Shakarian, an Armenian-American businessman, opened a small health food store originally named Lackzoom, in downtown Pittsburgh. He made US$35 on his first day and was able to open a second store within six months. Despite initial setbacks, such as the Ohio River flooding into downtown on St. Patrick's Day that wiped out both stores in 1936, Shakarian persevered and reopened the next year. He later expanded into mail-order sales of health foods, vitamins, and prescription drugs, capitalizing on the growing interest in physical fitness and health consciousness during the 1960s. In the 1960s, the company changed the name of its stores to General Nutrition Centers. Shakarian stepped down as chief executive officer in February 1984 but continued as chairman until his death later that year. Shakarian took GNC public (listed on the NYSE) in the 1980s. Gary Daum was named chief executive office in February 1984. In May 1985, Jerry Horn took on the role. GNC was taken private and sold to Thomas H. Lee Partners a PE investment/management fund in the late 1980s. Thomas Lee ran GNC and took it public prior to selling the company to Royal Dutch Numico and Numico acquired GNC in 1999; it sold GNC to Apollo Management in 2003. Ontario Teachers' Pension Plan and Ares Management bought GNC in 2007. GNC went public in 2011. In 1990, the company considered relocating but a public/private effort retained GNC headquarters in Downtown Pittsburgh.
== Cost == In Canada, PET scan funding varies by province. In Ontario, as of October 2025, there is no charge to the patient for any PET scans funded as part of the PET Scans Ontario Program. The program funds routine PET services for indications where sufficient evidence exists that the scan benefits the patient and offers advantages over other imaging tests. In the United States, PET scan costs vary significantly by location, facility type, and insurance status. According to Medicare's 2026 payment data, a whole-body PET scan has a national average total cost of $872, with the patient paying approximately $174 after Medicare coverage. In the United Kingdom, the National Health Service provides PET-CT scans free at point of use for eligible patients. In Australia, Medicare subsidies are available for eligible PET services.
Burton, Bonnie (October 15, 2014). "'Pink slime' in burgers? McDonald's hires former MythBuster to find out". CNET. Retrieved March 25, 2016. Runge, Kristin (March 23, 2016). "Pink Slimed: The Beef Industry Learns The Importance Of Social Media Literacy". Wisconsin Public Radio. Retrieved March 24, 2016.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
The dry powder is more stable during transport and storage than a solution. It also allows a known amount of material to be reconstituted at a chosen concentration.